Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA
Biotech
FDA rejects Biohaven approval request, triggering cost cutting
Biohaven responded to the rejection of its neurological disorder therapy by reprioritizing its pipeline to shrink its annual R&D spend by 60%.
Nick Paul Taylor
Nov 5, 2025 4:02am
Olympus updates corrective action related to 2023 lung scope recall
Nov 4, 2025 8:00am
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
uniQure's gene therapy for Huntington's hits FDA roadblock
Nov 3, 2025 10:03am
Electra shines with $183M fundraise for rare disease trial
Oct 22, 2025 8:26am
Lilly oncology head weighs in on FDA cancer drug policies
Oct 21, 2025 11:53am
